Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

PEDS-PLAN – Pediatric Precision Laboratory Advanced Neuroblastoma Therapy

ABSTRACT: PEDS-PLAN – Pediatric Precision Laboratory Advanced Neuroblastoma Therapy

PROVIDER: PRJNA683101 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

PEDS-PLAN – Pediatric Precision Laboratory Advanced Neuroblastoma Therapy

Project description:PEDS-PLAN – Pediatric Precision Laboratory Advanced Neuroblastoma Therapy

| PRJNA683102 | ENA

sponge body plan

Project description:sponge body plan

| PRJEB5970 | ENA

Real-time genomic characterization of advanced pancreatic cancer to enable precision medicine

Project description:Real-time genomic characterization of advanced pancreatic cancer to enable precision medicine

| PRJNA647948 | ENA

Real-time genomic characterization of advanced pancreatic cancer to enable precision medicine

Project description:Real-time genomic characterization of advanced pancreatic cancer to enable precision medicine

| PRJNA647949 | ENA

SNP data from Neuroblastoma samples

Project description:Neuroblastoma in advanced stages is among the most intractable pediatric cancers, even with the recent therapeutic advances. Neruroblastoma harbours a variety of genetic changes, including a high frequency of MYCN amplification, loss of heterozygosity in 1p36 and 11q, and gain of genetic material from 17q, all of which have been implicated in the pathogenesis of neuroblastoma. However, the scarcity of reliable molecular targets has hampered the development of effective therapeutic agents targeting neuroblastoma. We performed a genome-wide analysis of a large number of neuroblastoma samples, consisting of varying disease stages, permitted us to obtain a comprehensive registry of genomic lesions in neuroblastoma.

2008-10-10 | GSE12494 | GEO

Transcriptome Sequencing of Pediatric Neuroblastoma

Project description:<p>Neuroblastoma is the most common extra-cranial solid tumor in children. It represents 8% to 10% of all childhood cancers. Stage 4 Neuroblastoma is characterized by its clinical heterogeneous outcome. The special category, stage 4S tumors (2-5% of all NB) are chemo-sensitive, and the patients show spontaneous regression. On the other hand, MYCN amplification (25-30% of all NB) is associated with poor outcome of neuroblastoma, thus we further categorize stage 4 neuroblastoma into MYCN non-amplified and MYCN amplified group. Here we use transcriptome sequencing to characterize the transcriptome in 29 stage 4 Neuroblastoma samples.</p>

| phs000868 | dbGaP

Epigenetic subtypes of neuroblastoma [neuroblastoma]

Project description:Epigenetic subtypes of neuroblastoma [neuroblastoma]

| PRJNA559905 | ENA

TH-MYCN Mice with Caspase-8 Deficiency Develop Advanced Neuroblastoma with Bone Marrow Metastasis

Project description:Neuroblastoma, the most common extracranial pediatric solid tumor, is responsible for 15% of all childhood cancer deaths. Patients frequently present at diagnosis with metastatic disease, particularly to the bone marrow. Advances in therapy and understanding of the metastatic process have been limited due in part, to the lack of animal models harboring bone marrow disease. The widely employed transgenic model, the TH-MYCN mouse, exhibits limited metastasis to this site. Here we establish the first genetic immunocompetent mouse model for metastatic neuroblastoma with enhanced secondary tumors in the bone marrow. This model recapitulates two frequent alterations in metastatic neuroblasoma, over-expression of MYCN and loss of caspase-8 expression. In this model, the mouse caspase-8 gene was deleted in neural crest lineage cells by crossing a TH-Cre transgenic mouse with a caspase-8 conditional knockout mouse. This mouse was then crossed with the neuroblastoma prone TH-MYCN mouse. While over-expression of MYCN by itself rarely caused bone marrow metastasis (5% average incidence), combining MYCN overexpression and caspase-8 deletion significantly increased bone marrow metastasis (37% average incidence). Loss of caspase-8 expression did not alter the site, incidence, or latency of the primary tumors. However, secondary tumors were detected in the bone marrow of these mice as early as week 9-10. The mouse model described in this work is a valuable tool to enhance our understanding of metastatic neuroblastoma and treatment options and underscores the role of caspase-8 in neuroblastoma progression. Survey of spontateous 24 NB tumors and 5 bone marrow samples in wt and transgenic mice.

2013-05-22 | E-GEOD-42548 | biostudies-arrayexpress

TH-MYCN Mice with Caspase-8 Deficiency Develop Advanced Neuroblastoma with Bone Marrow Metastasis

2013-05-22 | E-GEOD-42254 | biostudies-arrayexpress

Kids First Pediatric Research Program in Neuroblastoma

Project description:Kids First Pediatric Research Program in Neuroblastoma

| PRJNA399223 | ENA